VerninoSBourneKMStilesLE, et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting—Part 1. Auton Neurosci. 2021;235:102828.
3.
MorrowAKMaloneLAKokorelisC, et al. Long-term COVID 19 sequelae in adolescents: the overlap with orthostatic intolerance and ME/CFS. Curr Pediatr Rep. 2022;10(2):31-44.
4.
SandroniPOpfer-GehrkingTLMcPheeBRLowPA. Postural tachycardia syndrome: clinical features and follow-up study. Mayo Clin Proc. 1999;74(11):1106-1110.
5.
MiglisMGPrietoTShaikRMuppidiSSinnDIJaradehS. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res. 2020;30(5):449-451.
6.
JohanssonMStåhlbergMRunoldM, et al. Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep. 2021;3(4):573-580.
PetracekLSSuskauerSJVickersRF, et al. Adolescent and young adult ME/CFS after confirmed or probable COVID-19. Front Med (Lausanne). 2021;8:668944.
9.
BlitshteynSWhitelawS. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;69(2):205-211.
10.
MorrowAKNgRVargasG, et al. Postacute/Long COVID in pediatrics: development of a multidisciplinary rehabilitation clinic and preliminary case series. Am J Phys Med Rehabil. 2021;100(12):1140-1147.
11.
RomaMMardenCLRowePC. Passive standing tests for the office diagnosis of postural tachycardia syndrome: new methodological considerations. Fatigue. 2018;6:179-192.
12.
FreemanRWielingWAxelrodFB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69-72.
13.
RomaMMardenCLDe WandeleIFrancomanoCARowePC. Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome. Auton Neurosci. 2018;215:89-96.
14.
RuziehMBaughADasaO, et al. Effects of intermittent intravenous saline infusions in patients with medication-refractory postural tachycardia syndrome. J Interv Card Electrophysiol. 2017;48(3):255-260.
15.
LiHYuXLilesC, et al. Autoimmune basis for postural tachycardia syndrome. J Am Heart Assoc. 2014;26:000755. doi:10.1161/JAHA.113.000755.
16.
GunningWT3rdKvaleHKramerPM, et al. Postural orthostatic tachycardia syndrome is associated with elevated G-protein coupled receptor autoantibodies. J Am Heart Assoc. 2019;17:013602.
17.
BarzilaiMJacobG. The effect of ivabradine on the heart rate and sympathovagal balance in postural tachycardia syndrome patients. Rambam Maimonides Med J. 2015;6(3):e0028.
18.
RuziehMSirianniNAmmariZ, et al. Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience. Pacing Clin Electrophysiol. 2017;40(11):1242-1245.
19.
McDonaldCFrithJNewtonJL. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011;13(3):427-430.
20.
TaubPRZadourianALoHCOrmistonCKGolshanSHsuJC. Randomized trial of ivabradine in patients with hyperadrenergic postural orthostatic tachycardia syndrome. J Am Coll Cardiol. 2021;77(7):861-871.
21.
Delle DonneGRosés NoguerFTillJSalukheTPrasadSKDaubeneyPEF. Ivabradine in postural orthostatic tachycardia syndrome: preliminary experience in children. Am J Cardiovasc Drugs. 2018;18(1):59-63.
22.
AnnamariaMLupoPPForestiS, et al. Treatment of inappropriate sinus tachycardia with ivabradine. J Interv Card Electrophysiol. 2016;46(1):47-53.
23.
SuttonRSalukheTVFranzen-McManusACCollinsALimPBFrancisDP. Ivabradine in treatment of sinus tachycardia mediated vasovagal syncope. Europace. 2014;16(2):284-288.
24.
O’SullivanJSLyneAVaughanCJ. COVID-19-induced postural orthostatic tachycardia syndrome treated with ivabradine. BMJ Case Rep. 2021;14(6):e243585.
